B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
B-CLL is the most prevalent leukemia in the Western hemisphere, accounting for ~25% of all leukemia's (1). This disease occurs virtually exclusively in the aging population, with the median age of diagnosis ranging between the mid 60s and the early 70s. Indeed, its occurrence before the age of 50 is quite unusual. This increase in occurrence with age is not unique to B-CLL; rather, it is characteristic several B cell lymphoproliferative disorders (e.g., non-Hodgkin's lymphoma, multiple myeloma). Gender and race also influence the development of B-CLL. Thus, the ratio of men: women is ~2:1 and the prevalence is increased in Caucasians. The rate of occurrence of B-CLL among Asians is significantly lower than for Caucasians and this does not increase with immigration to the West. DNA sequence analyses performed in our laboratory and in those of others indicate that B-CLL cells from unrelated patients share Ig V gene characteristics. These include the use of selected genes, the association of these genes with certain D and JH gene segments that code for unique CDR3 motifs, and the occasional occurrence of highly similar VHDJH + VLJL pairs. In ~50% cases, these rearranged genes are mutated, whereas in the others mutations are infrequent; this difference is related to the VH gene family used by the B-CLL cell.
| Condition |
|---|
|
Chronic Lymphocytic Leukemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging |
- expression of cell surface antigens HLA-DR and CD38+ markers in B-CLL cells compared to normal B-lymphocytes [ Time Frame: samples will be taken at the beginning, week 2, 4,6,8,12,and 24 (for blood), and bone marrow samples at weeks 2 and 6. ] [ Designated as safety issue: No ]
Biospecimen Description:
Blood cells, tissue
| Estimated Enrollment: | 1000 |
| Study Start Date: | July 1998 |
| Estimated Study Completion Date: | January 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Chronic Lymphocytic Leukemia Community Sample
Inclusion Criteria:
- 18 years of age Patients must be willing to be contacted in the future
Exclusion Criteria:
- Patients who are known to be anemic, with a hemoglobin <8 PAtients who are known to be infected with HIV
Contacts and Locations| United States, New York | |
| Feinstein Institute for Medical Research | |
| Manhasset, New York, United States, 11030 | |
| Principal Investigator: | Nicholas Chiorazzi, MD | North Shore-LIJ Health System |
More Information
No publications provided
| Responsible Party: | North Shore Long Island Jewish Health System |
| ClinicalTrials.gov Identifier: | NCT01028430 History of Changes |
| Other Study ID Numbers: | 04-046 |
| Study First Received: | December 8, 2009 |
| Last Updated: | February 5, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by North Shore Long Island Jewish Health System:
|
Chronic Lymphocytic Leukemia |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Neoplasms by Histologic Type Neoplasms |
Leukemia, B-Cell Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013